BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22918564)

  • 1. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies.
    Schmidt N; Hess V; Zumbrunn T; Rothermundt C; Bongartz G; Potthast S
    Eur Radiol; 2013 Mar; 23(3):632-9. PubMed ID: 22918564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
    Thian Y; Gutzeit A; Koh DM; Fisher R; Lote H; Larkin J; Sohaib A
    Radiology; 2014 Nov; 273(2):452-61. PubMed ID: 24869795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
    Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
    AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
    van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Haanen JB; Boven E
    Br J Cancer; 2010 Mar; 102(5):803-9. PubMed ID: 20145618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response.
    Mytsyk Y; Pasichnyk S; Dutka I; Dats I; Vorobets D; Skrzypczyk M; Uteuliyev Y; Botikova A; Gazdikova K; Kubatka P; Urdzik P; Kruzliak P
    Clin Exp Med; 2020 May; 20(2):277-287. PubMed ID: 32026157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria.
    Schramm N; Englhart E; Schlemmer M; Hittinger M; Übleis C; Becker CR; Reiser MF; Berger F
    Eur J Radiol; 2013 Jun; 82(6):951-8. PubMed ID: 23518148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Choi response criteria for inferior vena cava tumor thrombus in renal cell carcinoma treated with targeted therapy.
    Kwon T; Lee JL; Kim JK; You D; Jeong IG; Song C; Ahn H; Kim CS; Hong JH
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1751-8. PubMed ID: 24841738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
    Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
    Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
    Krajewski KM; Franchetti Y; Nishino M; Fay AP; Ramaiya N; Van den Abbeele AD; Choueiri TK
    Oncologist; 2014 May; 19(5):507-14. PubMed ID: 24755461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.
    Nathan PD; Vinayan A; Stott D; Juttla J; Goh V
    Cancer Biol Ther; 2010 Jan; 9(1):15-9. PubMed ID: 20009542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC).
    Gupta S; Kang HC; Sun J; Matrana MR; Tannir NM; Choi H
    Abdom Radiol (NY); 2020 Jun; 45(6):1872-1882. PubMed ID: 31822966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response.
    Lamuraglia M; Raslan S; Elaidi R; Oudard S; Escudier B; Slimane K; Penna RR; Wagner M; Lucidarme O
    Eur Radiol; 2016 Jan; 26(1):278-85. PubMed ID: 25953002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
    Wu G; Liu G; Kong W; Qu J; Suo S; Liu X; Xu J; Zhang J
    Eur Radiol; 2017 Sep; 27(9):3574-3582. PubMed ID: 28130612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
    Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
    Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of clinical outcomes of antiangiogenic-targeted therapy in patients with pulmonary metastatic renal cell carcinoma using non-contrast-enhanced computed tomography.
    Wu GY; Suo ST; Kong W; Jin D; Zhang J; Xu JR
    Acad Radiol; 2014 Nov; 21(11):1434-40. PubMed ID: 25097010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
    Iacovelli R; Lanoy E; Albiges L; Escudier B
    BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria.
    Lee HY; Lee KS; Hwang HS; Lee JW; Ahn MJ; Park K; Kim TS; Yi CA; Chung MJ
    Korean J Radiol; 2010; 11(6):618-26. PubMed ID: 21076587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.